Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal

Inclusion Criteria: * Subject can provide written informed consent. * Chronic non-cancer pain diagnosis such as low back pain, chronic neck pain, osteoarthritis, and prolonged post-surgical pain with daily pain for a minimum of 6 months. * Self-reported use of prescribed oral opioid medication(s) (tablets, pills or capsules) of at least 50 morphine mg equivalent (MME) but no higher than 240 mg MME daily or near daily (≥5 days per week) for at least 12 weeks and seeking to discontinue their opioid medication. * Willing to be treated with non-opioid treatments for pain (in addition to opioid being tapered) for duration of study. * Willing to abstain from alcohol use during the study. * Willing to partner with his or her pain physician on a subject-centered pain management plan during the study. * In generally good health, in the opinion of the Investigator, other than the underlying chronic pain syndrome * Women of childbearing potential must have a negative pregnancy test at Screening. * Non-pregnant, non-lactating women who are postmenopausal, naturally or surgically sterile, or who agree to use acceptable contraceptive methods throughout the course of the study. * Other criteria will be discussed in detail with potential subjects by Site Investigator Exclusion Criteria: * Has a primary diagnosis of complex regional pain syndrome, central neuropathic pain, somatoform pain syndromes, acute nerve root compression, any acute or progressive infectious, inflammatory, or neurolo…